CBN Oil 500 mg by Steve's Goods

INSUFFICIENT RELIABLE EVIDENCE to RATE

• Insomnia. Sublingual cannabinol has only been evaluated in combination with other ingredients; its effect when used alone is unclear. Details: A clinical trial in patients with self-reported insomnia shows that using an investigational drug (ZLT-101; Zelira Therapeutics) containing cannabinol 2 mg/mL, delta-9-tetrahydrocannabinol (THC) 20 mg/mL, and cannabidiol (CBD) 1 mg/mL, taken as 0.5-1 mL sublingually one hour before sleep for 2 weeks, improves symptom severity and total sleep time when compared with placebo (108677). The validity of this finding is limited by the short duration of treatment. More evidence is needed to rate cannabinol for this use.

(Read more about CANNABINOL (CBN))

CYTOCHROME P450 1A1 (CYP1A1) SUBSTRATES Interaction Rating = Moderate Be cautious with this combination. Severity = Moderate •  Occurrence = Possible •  Level of Evidence = D Theoretically, taking cannabinol with CYP1A1 substrates might decrease the clearance of these drugs and increase their effects.  Details In vitro research shows that cannabinol modestly inhibits CYP1A1 enzymes (89690). So far, this interaction has not been reported in humans.

CYTOCHROME P450 2B6 (CYP2B6) SUBSTRATES Interaction Rating = Moderate Be cautious with this combination. Severity = Moderate •  Occurrence = Possible •  Level of Evidence = D Theoretically, cannabinol might increase the levels and clinical effects of CYP2B6 substrates.  Details In vitro research shows that cannabinol potently inhibits CYP2B6 enzymes (107325). So far, this interaction has not been reported in humans.

CYTOCHROME P450 2C9 (CYP2C9) INHIBITORS Interaction Rating = Moderate Be cautious with this combination. Severity = Moderate •  Occurrence = Possible •  Level of Evidence = D Theoretically, CYP2C9 inhibitors might increase the levels and clinical effects of cannabinol.  Details In vitro research shows that CYP2C9 enzymes are involved in the 11-hydroxylation of cannabinol (101670). So far, this interaction has not been reported in humans.

CYTOCHROME P450 2C9 (CYP2C9) SUBSTRATES Interaction Rating = Moderate Be cautious with this combination. Severity = Moderate •  Occurrence = Possible •  Level of Evidence = D Theoretically, cannabinol might increase the levels and clinical effects of CYP2C9 substrates.  Details In vitro research shows that cannabinol potently inhibits CYP2C9 enzymes (107325). So far, this interaction has not been reported in humans.

CYTOCHROME P450 2E1 (CYP2E1) SUBSTRATES Interaction Rating = Moderate Be cautious with this combination. Severity = Moderate •  Occurrence = Possible •  Level of Evidence = D Theoretically, cannabinol might increase the levels and clinical effects of CYP2E1 substrates.  Details In vitro research shows that cannabinol potently inhibits CYP2E1 enzymes (107325). So far, this interaction has not been reported in humans.

CYTOCHROME P450 3A4 (CYP3A4) INHIBITORS Interaction Rating = Moderate Be cautious with this combination. Severity = Moderate •  Occurrence = Possible •  Level of Evidence = D Theoretically, CYP3A4 inhibitors might increase the levels and clinical effects of cannabinol.  Details In vitro research shows that CYP3A4 enzymes are involved in the 8-hydroxylation of cannabinol (101670). So far, this interaction has not been reported in humans.

(Read more about CANNABINOL (CBN))

General ...No adverse effects have been reported; however, a thorough evaluation of safety outcomes has not been conducted.

(Read more about CANNABINOL (CBN))